Goldman Sachs Upgrades ResMed (RMD) to Buy; See Continued Double-Digit Growth
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $224.46 -1.01%
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs upgraded ResMed (NYSE: RMD) from Neutral to Buy.
Goldman analyst said, "We see continued double-digit growth in mask revenues given the robust outlook for the installed base of users as well as market share gains given RMD’s ongoing product innovation. The shift to APAP flow gens also appears to have resumed. This in turn is likely to support gross margins above 60%. With growth at an EPS level enhanced by a declining tax rate and share count, we believe that it is likely that RMD can achieve doubledigit EPS growth into the medium term."
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $32.05 yesterday.
Goldman analyst said, "We see continued double-digit growth in mask revenues given the robust outlook for the installed base of users as well as market share gains given RMD’s ongoing product innovation. The shift to APAP flow gens also appears to have resumed. This in turn is likely to support gross margins above 60%. With growth at an EPS level enhanced by a declining tax rate and share count, we believe that it is likely that RMD can achieve doubledigit EPS growth into the medium term."
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $32.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- HSBC Upgrades Digital Realty Trust (DLR) to Buy
- Canaccord Upgrades HLS Therapeutics (HLS:CN) (HLTRF) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
